**(See the editorial commentary by Gilbert on pages 1687--9.)**

Lower respiratory tract infection (LRTI) commonly causes adult hospitalization, and viruses account for many of these illnesses \[[@JIV252C1]--[@JIV252C4]\]. Increased availability of multiplex polymerase chain reaction (PCR) assays allows clinical laboratories to rapidly detect a wide variety of respiratory viruses \[[@JIV252C5], [@JIV252C6]\]. Despite viral detection, most patients in US hospitals receive broad-spectrum antibiotics, partly because of concerns about bacterial coinfection \[[@JIV252C7]--[@JIV252C9]\]. Reports from Europe suggest that elevated serum procalcitonin (PCT) levels predict bacterial infection and that PCT algorithms can be used to safely guide antibiotic use in LRTI, resulting in significant reductions in antibiotic duration \[[@JIV252C10], [@JIV252C11]\]. However, PCT-based treatment algorithms for respiratory infections have not been widely adopted in the United States \[[@JIV252C12]--[@JIV252C14]\]. In a prior study of adults hospitalized with respiratory illnesses, we showed that viral infection was common and that, of those with viruses, 60% had no evidence of bacterial infection, although most received antibiotics \[[@JIV252C15]\]. Results of a post-hoc physician survey indicated a perception that serum biomarkers coupled with viral testing would be most helpful to guide antibiotic decisions. Nevertheless, confidence in PCT-guided algorithms among US physicians will likely be an iterative process. Moreover, because early diagnosis and treatment with antibiotics is recommended by professional societies for patients hospitalized with pneumonia and mandated in clinical practice, the potential to prevent inappropriate antibiotic use in the setting of viral LRTI is likely greatest in the population of patients without clinical and diagnostic evidence of a definite pneumonic process. We therefore believe that initial US clinical trials for PCT-guided care of LRTI should focus on persons at lower risk for invasive bacterial disease and without definitive pneumonia. Thus, we investigated the feasibility of conducting PCT-based algorithm trials in a US hospital and the value of concurrent viral testing to reduce unnecessary antibiotic use in adults hospitalized with nonpneumonic LRTI.

METHODS {#s2}
=======

Study Design {#s2a}
------------

The trial was designed as a 1-year open label randomized clinical trial in which 300 patients hospitalized with non-pneumonic LRTI were randomized 1:1 to standard care or PCT-guided care in combination with multiplex viral PCR testing. The trial was registered on ClinicalTrials.gov (NCT01907659).

Site {#s2b}
----

Rochester General Hospital (RGH), a 528-bed community hospital in Rochester, New York, was the study site. RGH uses an electronic medical record (EMR), and most inpatients are cared for by staff of the Department of Internal Medicine. A duplex PCR for influenza virus and respiratory syncytial virus (RSV; hereafter, "hospital PCR") is routinely available, and PCT testing is only available for patients in intensive care units (ICUs). RGH was also the site of a previous respiratory illness surveillance study (conducted during 2008--2011), for which the study population and inclusion criteria were identical to those for the present study \[[@JIV252C15]\].

Information Sessions {#s2c}
--------------------

Prior to the study, physicians and midlevel providers (nurse practitioners and physician assistants) were formally educated regarding results of the previous surveillance study, causes of respiratory infections, antibiotic guidelines and antibiotic complications, and the use of PCT algorithms to guide antibiotic therapy.

Subject Recruitment {#s2d}
-------------------

Adults ≥21 years of age with symptoms compatible with LRTI (ie, admission diagnosis of pneumonia, acute exacerbations of chronic obstructive pulmonary disease \[COPD\], bronchitis, asthma, influenza, viral syndrome, respiratory failure, and congestive heart failure \[CHF\]) were identified by reviewing the daily admission census. Patients with characteristics indicative of a high risk for bacterial infection (ie, ICU requirement, active chemotherapy or radiation, immunosuppression, definitive infiltrate on chest radiograph, enrollment systolic blood pressure of \<90 mm Hg, and ≥15% band forms in peripheral blood) were excluded. Infiltrates were considered definitive if they were characterized as "unequivocal" on a radiology report. Persons with a clinical diagnosis of pneumonia on admission but ambiguous chest radiograph findings, such as a "possible infiltrate" or "infiltrate versus atelectasis," were not excluded. Patients who had conditions known to increase PCT levels (ie, trauma, renal failure, and pancreatitis) or who received antibiotics prior to admission were excluded. Subjects or their healthcare representative provided written informed consent and the study approved by the RGH and University of Rochester institutional review boards.

Enrollment Procedures {#s2e}
---------------------

Enrollment was conducted in the morning within 24 hours after admission. At enrollment, demographic, clinical, and laboratory information and nose and throat swab specimens for PCR were collected. Serum samples were collected at admission and at least 12 hours later for PCT testing. Subjects were stratified by the presence of COPD and were randomly assigned at a ratio of 1:1, using blocks of 4, to receive standard care or the intervention. Notation was placed in the EMR for all subjects to indicate their study participation. Subjects randomly assigned to the intervention group had PCT and viral testing performed immediately. Subjects in the standard care group had samples frozen and tested at study termination.

Standard Care {#s2f}
-------------

Standard of care testing (bacterial and viral cultures of respiratory samples, hospital influenza/RSV duplex PCR \[hospital PCR\], and urine legionella antigen analysis) were obtained at the discretion of the providing team. The turnaround time for the hospital PCR was generally 1--2 hours after the sample was received. Urine pneumococcal antigen was not available in the hospital during the study period. Antibiotic decisions were made by the attending physician without intervention by investigators.

Intervention {#s2g}
------------

All standard of care diagnostic tests (bacterial and viral cultures of respiratory samples, hospital PCR, and urine legionella antigen analyses) were ordered at the discretion of the care-providing team. Serum PCT and viral/atypical pathogen PCR testing were performed as soon as possible. Two serum PCT levels were obtained, and the higher of the 2 was used for algorithm interpretation and data analysis. Results were reported in the EMR 2--3 hours after enrollment, and the treating team notified by a text sent via page and by a simultaneous e-mail providing the PCT algorithm. The algorithm was also available on the hospital website and previously distributed pocket cards. The following information was communicated: "Serum PCT is a biomarker associated with bacterial infection, and can be used to guide therapy according to the highest value on admission OR at 12--24 hours. However, PCT is not a substitute for clinical judgment. For PCT values of ≤0.1 ng/mL, initiation of antibiotic treatment is strongly discouraged; for values of 0.11--0.24 ng/mL, initiation is discouraged; for values of 0.25--0.49 ng/mL, initiation is encouraged; and for values of ≥0.5 ng/mL, initiation is strongly encouraged."

Hospital Course Evaluation and Illness Follow-up {#s2h}
------------------------------------------------

Study personnel reviewed the EMR daily until discharge, with attention to antibiotic use and safety outcomes (progression or new pneumonia, lung abscess, empyema, ICU care, respiratory failure, and death). A serious adverse event (SAE) was defined as ICU transfer or death within 30 days of enrollment. All SAEs were reviewed by an independent data safety monitoring board. Subjects were contacted by phone at 30 days and 3 months by personnel blinded to randomization, who collected information about healthcare utilization, antibiotic use and complications, and return to baseline health.

Laboratory Methods {#s2i}
------------------

### Serum PCT Level {#s2i1}

Serum PCT levels were measured by VIDAS BRAHMS (bioMerieux), using the enzyme-linked fluorescent assay technique. The assay range is 0.05--200 ng/mL.

### Multiplex PCR {#s2i2}

Nose and throat swab specimens were tested using the FilmArray Respiratory Panel (FilmArray; Idaho Technologies, Salt Lake City, Utah), which detects 14 common respiratory viruses (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A virus, influenza B virus, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, and respiratory syncytial virus) and 3 atypical bacteria (*Bordetella pertussis, Chlamydophila pneumoniae*, and *Mycoplasma pneumoniae*).

End Points {#s2j}
----------

The feasibility end point for the trial was the ability to recruit and randomly assign 300 subjects in a 12-month period. The primary impact end point was duration of antibiotic therapy. A day of antibiotic therapy was defined as any day in which any doses of antibiotics were administered. Other measures of antibiotic exposure included discontinuation of antibiotics within 48 hours and discharge receiving antibiotics. Seven subjects discharged receiving long-term antibiotic therapy for antiinflammatory properties were excluded from the analyses comparing the number of subjects discharged receiving antibiotics. Safety was assessed during the hospital stay, at 1 and 3 months. Safety end points included length of hospital stay and, 1 and 3 months after discharge, respiratory complications, ICU care, death, and healthcare utilization.

Statistical Analysis {#s2k}
--------------------

Sample size was chosen to ensure the feasibility of a 1-year pilot study, and therefore formal sample size and power calculations were not performed. Categorical variables were summarized by counts and proportions and compared using the Fisher exact test. Medians and interquartile ranges (IQRs) were used to describe continuous variables, with comparisons performed using the nonparametric Wilcoxon test. For intervention patients with a PCT level of; ≤0.24 ng/mL, logistic regression was used to model algorithm compliance as a function of clinical covariates, including age, length of symptoms prior to admission, sputum culture results, signs and symptoms of illness, admission diagnosis, chest radiograph results, PCT level, and viral testing. SAS 9.4 was used for all analyses, with tests performed at the 2-sided 0.05 level.

RESULTS {#s3}
=======

Subject and Illness Characteristics {#s3a}
-----------------------------------

The planned sample size of 300 subjects was achieved in 7 months. From October 2013 through April 2014, 685 hospitalized patients were assessed; 151 eligible patients were randomly assigned to the intervention group, and 149 were randomly assigned to the nonintervention group ([Figure 1](#JIV252F1){ref-type="fig"}). The 2 groups were well matched for demographic characteristics, underlying medical conditions, admission diagnoses, and severity of illness, with the exception that a significantly greater percentage patients with CHF was randomly assigned to the nonintervention group ([Table 1](#JIV252TB1){ref-type="table"}). The most common admission diagnoses in both groups were acute exacerbations of COPD (38%--39%), asthma exacerbation (18%--21%), pneumonia (19%), CHF (6%--11%), and influenza (6%--7%).

###### 

Patient Characteristics

  Characteristic                     Intervention Group (n = 151)   Nonintervention Group (n = 149)   *P* Value
  ---------------------------------- ------------------------------ --------------------------------- -----------
  Age, y                             61 (51--72)                    64 (50--74)                       .41
  Female sex                         88 (58)                        80 (54)                           .49
  Race/ethnicity                                                                                      
   Black                             53 (35)                        37 (25)                           .06
   White                             98 (65)                        111 (75)                          .08
   Hispanic                          12 (8)                         16 (11)                           .43
  Underlying condition                                                                                
   Current/former smoker             123 (81)                       126 (85)                          .54
   Diabetes mellitus                 60 (40)                        48 (32)                           .19
   COPD                              72 (48)                        66 (44)                           .56
   CHF                               33 (22)                        50 (34)                           .03
   Asthma                            47 (31)                        41 (28)                           .53
   Hypertension                      88 (58)                        92 (62)                           .56
  Sign/symptom                                                                                        
   Fever^a^                          32 (21)                        30 (20)                           .88
   Cough                             138 (91)                       134 (90)                          .70
   Wheeze                            125 (83)                       126 (85)                          .76
   Dyspnea                           140 (93)                       136 (91)                          .68
   Sputum production                 118 (78)                       92 (62)                           .002
  Admission diagnosis                                                                                 
   Pneumonia                         28 (19)                        29 (19)                           .88
   Influenza                         9 (6)                          11 (7)                            .65
   CHF                               9 (6)                          16 (11)                           .15
   COPD                              58 (39)                        58 (38)                           .99
   Asthma                            32 (21)                        27 (18)                           .56
  Laboratory finding                                                                                  
   WBC count, ×10^3^ cells/µL        9.1 (6.5--11.5)                9.3 (7.3--12.1)                   .50
   CURB-65 score                     1.0 (0.0--2.0)                 2.0 (1.0--2.0)                    .16
  Chest radiography finding^b^                                                                        
   No acute disease                  72 (49)                        87 (58)                           .10
   Possible infiltrate               41 (28)                        26 (17)                           .03
  Viral diagnosis                                                                                     
   Test type                                                                                          
    FilmArray PCR^c^                 63 (42)                        64 (40)                           .99
    Hospital PCR^d^                  20 (13)                        28 (19)                           .26
   PCR-positive result               64 (42)                        64 (43)                           
  Bacterial diagnosis                                                                                 
   Test type                                                                                          
    PCR                              2 (1)                          1 (1)                             .99
    Culture                          13 (9)                         12 (8)                            .99
   Admission PCT level, ng/mL^c,e^   0.05 (0.05--0.11)              0.05 (0.05--0.11)                 .65
    ≤0.10                            112 (74)                       107 (74)                          .99
    0.11--0.24                       14 (9)                         19 (13)                           .36
  0.25--0.50                         10 (7)                         10 (7)                            .99
  ≥0.50                              15 (10)                        9 (6)                             .29

Data are no. (%) of patients or median value (interquartile range). See "Methods" section for descriptions of the intervention and nonintervention groups.

Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; PCR, polymerase chain reaction; PCT, procalcitonin; WBC, white blood cell.

^a^ Defined as a temperature of ≥38°C.

^b^ Three intervention patients did not undergo chest radiography.

^c^ Data for nonintervention patients were not available to clinicians during the trial.

^d^ Defined as a duplex PCR for influenza virus and respiratory syncytial virus.

^e^ Four nonintervention patients did not have the PCT level measured.

![Flow of patients through the study. Reasons for exclusion from the study included intensive care unit (ICU) stay, antibiotic use for \>24 hours prior to enrollment, active chemotherapy, conditions known to increase procalcitonin level (eg, renal failure, pancreatitis, and trauma), definite infiltrate on a chest radiograph (according to radiology report), \>15% bands on a peripheral blood smear, and a systolic blood pressure (SBP) of \<90 mm Hg at enrollment. Abbreviation: PCT, procalcitonin.](jiv25201){#JIV252F1}

Laboratory Data {#s3b}
---------------

Overall, 132 viral diagnoses (64 in the intervention group and 64 in the nonintervention group) were made by any means in 128 subjects (4 subjects had 2 distinct viruses). FilmArray testing was performed for all intervention subjects during the study period and for all nonintervention subjects after study completion. In the intervention group, hospital PCR detected influenza virus or RSV in 13%, whereas the FilmArray test detected viral RNA in 42%. Notably, 19% of nonintervention subjects had positive results of hospital PCR, which was available to treating physicians; the most common viruses detected were influenza A virus (in 33% of cases), rhinovirus (19%), RSV (17%), human coronavirus (14%), and human metapneumovirus (8%).

The majority of patients in both groups had low admission PCT values (≤0.24 ng/mL; [Table 1](#JIV252TB1){ref-type="table"}). All 151 intervention patients had data on their serum PCT level at admission, and 139 had data from a subsequent measurement performed on day 2 of hospitalization. Of the 126 intervention subjects with an initial low PCT value, 5 had a higher second level, resulting in 121 intervention subjects with PCT values of ≤0.24 ng/mL at both time points.

Bacterial diagnoses were made among 9%--10% of patients, with most made on the basis of sputum culture results and 25% associated with high PCT levels (\>0.24 ng/mL). Three patients had positive results of a FilmArray assay for atypical bacteria, and illnesses in all 3 were associated with low serum PCT levels. There were 216 bacterial blood cultures performed for subjects in both arms, and all but 1 had negative results. The exception involved 1 nonintervention patient, who had *Streptococcus pneumoniae* bacteremia. This illness was associated with a high serum PCT level on admission.

Primary Outcomes {#s3c}
----------------

Antibiotic exposure was measured on the basis of discontinuation of antibiotic treatment within 48 hours, discharge receiving oral antibiotics, and total duration of therapy ([Table 2](#JIV252TB2){ref-type="table"}). There were no significant differences in duration of antibiotic therapy between intervention and nonintervention patients, although there was a trend toward a decreased number of intervention patients discharged receiving antibiotics (35% vs 44%; *P* = .09; [Table 2](#JIV252TB2){ref-type="table"}*A*).

###### 

Comparison of Antibiotic Use Between the Intervention Group/Subgroups or Historical Controls and the Nonintervention Group

  Characteristic                          Intervention Group                                             Nonintervention Group   *P* Value
  --------------------------------------- -------------------------------------------------------------- ----------------------- -----------
  Subjects, no.                           151                                                            149                     
  Antibiotic use for ≤48 h                69 (46)                                                        61 (41)                 .42
  Discharged receiving oral antibiotics   51 (35)^a^                                                     64 (44)^b^              .09
  Total antibiotic-days                   3.0 (1.0--7.0)                                                 4.0 (0.0--8.0)          .71
                                          Intervention Subgroup Positive for Virus With Low PCT Values   Nonintervention Group   
  Subjects, no.                           49                                                             149                     
  Antibiotic use for ≤48 h                28 (57)                                                        61 (41)                 .07
  Discharged receiving oral antibiotics   10 (20)                                                        64 (45)^b^              .002
  Total antibiotic-days                   2.0 (1.0--6.0)                                                 4.0 (0.0--8.0)          .11
                                          Intervention Subgroup Adherent to Algorithm                    Nonintervention Group   
  Subjects, no.                           96                                                             149                     
  Antibiotic use for ≤48 h                63 (65)                                                        61 (41)                 .002
  Discharged receiving oral antibiotics   19 (20)^c^                                                     64 (45)^b^              .002
  Total antibiotic-days                   2.0 (0.0--3.0)                                                 4.0 (0.0--8.0)          .004
                                          Historical Controls                                            Nonintervention Group   
  Subjects, no.                           586                                                            149                     
  Antibiotic use for ≤48 h                150 (24)                                                       61 (41)                 \<.001
  Discharged receiving oral antibiotics   342 (56)^d^                                                    64 (45)^b^              .003
  Total antibiotic-days                   6.0 (2.0--9.0)                                                 4.0 (0.0--8.0)          \<.001

Data are no. (%) of patients or median no. (interquartile range). See "Methods" section for descriptions of the intervention and nonintervention groups and the historical controls.

Abbreviation: PCT, procalcitonin.

^a^ Data are for 147 subjects.

^b^ Data are for 144 subjects.

^c^ Data are for 93 subjects.

^d^ Data are for 616 subjects.

When antibiotic exposure in the intervention subgroup with presumably the lowest risk for bacterial infection (ie, patients who tested positive for virus and had a low PCT level) was compared to that in the nonintervention group, we noted a trend toward fewer days of antibiotics prescribed (median, 2 days \[IQR, 1--6 days\] vs 4 days \[IQR, 0--8 days\]; *P* = .11), with significantly fewer patients discharged receiving antibiotics (20% vs 45%; *P* = .002; [Table 2](#JIV252TB2){ref-type="table"}*B* and [Figure 2](#JIV252F2){ref-type="fig"}). Analysis of antibiotic use among subjects for whom treating physicians adhered to the algorithm revealed a significantly shorter duration of therapy, compared with the duration among nonintervention subjects (median, 2 days \[IQR, 0--3 days\] vs 4 days \[IQR, 0--8 days\]; *P* = .004; [Table 2](#JIV252TB2){ref-type="table"}*C*).

![Time series plot of total antibiotic days in intervention and nonintervention patients and a subgroup analysis of virus-positive intervention subjects with low procalcitonin (PCT) levels, compared with the nonintervention arm. Abbreviation: IQR, interquartile range.](jiv25202){#JIV252F2}

Consistent with these findings, intervention subjects with low PCT values were less likely to receive antibiotics for ≥48 hours or at discharge than those with high PCT levels ([Table 3](#JIV252TB3){ref-type="table"}*A*). The total duration of antibiotic therapy were also shorter for subjects with low PCT levels (median, 2 days \[IQR, 0--6 days\] vs 7.5 days \[IQR, 5--10 days\]; *P* \< .001; [Table 3](#JIV252TB3){ref-type="table"}*A*). However, patients with high PCT values also had higher CURB-65 scores (median, 2 \[IQR, 1--3\] vs 1 \[IQR, 0--2\]; *P* = .001), and a greater percentage showed possible infiltrates on chest radiograph (40% vs 25%; *P* = .12). Additional subgroup analyses assessing the added value of viral testing to PCT algorithms were performed. Patients with a known viral diagnosis during hospitalization (64 in the intervention group and 28 in the nonintervention group) were less frequently discharged receiving antibiotics (28% vs 45%; *P* = .01), with a trend toward a shorter duration of therapy (median, 2 days \[IQR, 1--6 days\] vs 4 days \[IQR, 1--8 days\]; *P* = .07; [Table 3](#JIV252TB3){ref-type="table"}*B*), compared with those without a viral diagnosis.

###### 

Comparison of Antibiotic Use in the Intervention Group, by Procalcitonin (PCT) Level, and Among All Patients, by Results of Viral Testing

  Characteristic                          Low PCT Level    High PCT Level    *P* Value
  --------------------------------------- ---------------- ----------------- -----------
  Subjects, no.                           121              30                
  Antibiotic use for ≤48 h                63 (52)          6 (20)            .002
  Discharged receiving oral antibiotics   32 (27)^a^       19 (63)           \<.001
  Total antibiotic-days                   2.0 (0.0--6.0)   7.5 (5.0--10.0)   \<.001
                                          Virus Positive   Virus Negative    
  Subjects, no.                           92               208               
  Antibiotic use for ≤48 h                47 (51)          83 (40)           .08
  Discharged receiving oral antibiotics   26 (28)          89 (45)^b^        .01
  Total antibiotic-days                   2.0 (1.0--6.0)   4.0 (1.0--8.0)    .07

Data are no. (%) of patients or median no. (interquartile range). See "Methods" section for descriptions of the intervention and nonintervention groups.

^a^ Data are for 117 subjects.

^b^ Data are for 198 subjects.

We also investigated the possibility of a study effect on the nonintervention arm resulting from prestudy educational sessions and from subjects in both arms receiving care from the same providers. Primary outcomes for the nonintervention group were compared to those for matched historical control subjects who were hospitalized at RGH with LRTI during a 2008--2011 surveillance study and were deemed, using the identical criteria, to be at low risk for bacterial infection \[[@JIV252C15]\]. There were no significant differences in demographic characteristics, admission diagnoses, and illness severity between the groups. However, compared with historical controls, there were significant decreases in antibiotic exposure in the nonintervention group, most notably a 2-day decrease in the duration of antibiotic therapy (median, 6 days \[IQR, 2--9 days\] vs 4 days \[IQR, 0--8 days\]; *P* \< .001; [Table 2](#JIV252TB2){ref-type="table"}*D*).

Secondary Outcomes {#s3d}
------------------

Safety was assessed during the hospital stay, at 1 and 3 months. No deaths occurred during hospitalization, and 4 SAEs occurred in each arm of the study, with none judged to be related to the intervention. One intervention patient and 4 nonintervention patients developed a new cases of pneumonia within 30 days. The median length of hospital stay was 4 days in both groups, and the number of posthospitalization healthcare visits was similar. Of note, the length of illness (assessed from the onset of symptoms prior to hospitalization to the subject\'s report of a return to baseline) was shorter in intervention patients (median, 16 days \[IQR, 12--24 days\] vs 20 days \[IQR, 13--28 days\]; *P* = .03). There were 27 potential antibiotic adverse events (rash, gastrointestinal symptoms, fungal overgrowth, or resistant flora) in the intervention arm and 28 in the nonintervention arm. Three cases of *Clostridium difficile* colitis occurred in nonintervention patients, compared with none in the intervention group. At 3 months, there were no significant differences in any of the clinical safety outcomes for the intervention arm or the subgroup of algorithm-adherent intervention subjects, compared with nonintervention patients.

Healthcare Provider Adherence to the Algorithm {#s3e}
----------------------------------------------

Overall, algorithm adherence was 64%, although providers were more likely to prescribe antibiotics for patients with high PCT values than to withhold antibiotics for patients with low PCT values ([Figure 3](#JIV252F3){ref-type="fig"}). The majority of providers (77%) followed algorithm recommendations to continue antibiotic treatment when PCT values were high, although it was notable that antibiotic therapy was discontinued in 5 subjects with high PCT values. In contrast, providers followed algorithm recommendations to discontinue antibiotics in 61% of subjects for whom a low PCT value was detected. The only variable associated with algorithm nonadherence in subjects with low PCT values was an admission diagnosis of pneumonia (26% vs 7%; *P* = .01).

![Provider response to the procalcitonin (PCT)--guided treatment algorithm. A circle represents an individual PCT value for each intervention study subject. The horizontal bar represents the threshold for PCT values (0.24 ng/mL), which defines levels as either low or high. The algorithm discourages antibiotic use below this threshold and recommends antibiotics for values above this level. Results are segregated by provider response to the algorithm and are designated as "algorithm followed" and "algorithm rejected."](jiv25203){#JIV252F3}

DISCUSSION {#s4}
==========

This is the first study combining PCT measurement with molecular viral diagnostic testing, as well as the first randomized clinical trial performed solely in the United States that evaluated PCT-guided care for patients hospitalized with respiratory illnesses. Although overall antibiotic exposure was similar in the intervention and nonintervention arms, subgroup analyses and comparison with historical controls were encouraging because they suggested that US physicians will respond to viral and biomarker data to inform antibiotic use. The primary goal of our study was to evaluate the feasibility of conducting randomized clinical trials of PCT-guided antibiotic recommendations in the United States. Our data clearly indicate that such trials are likely to be well received, since complete enrollment was achieved 5 months early.

Evidence is mounting that PCT-guided treatment of respiratory infections can safely reduce antibiotic use \[[@JIV252C10], [@JIV252C16]--[@JIV252C20]\]. European trials have been performed in a variety of settings, including emergency departments, primary care offices, hospitals, and ICUs \[[@JIV252C10], [@JIV252C16], [@JIV252C17], [@JIV252C19]--[@JIV252C25]\]. In all prior studies, antibiotic use was decreased without harm, as measured by composite adverse event outcomes. The largest trial to date was a Swiss multicenter randomized trial of PCT-guided therapy in 1359 hospitalized patients with LRTI \[[@JIV252C16]\]. A 35% decrease in overall antibiotic exposure was reported without notable differences in short-term or long-term outcomes. Currently, use of PCT levels in the United States is only approved for management of sepsis \[[@JIV252C11], [@JIV252C26]\]. The only US data on PCT-guided care for patients with LRTI comes from the ProREAL study, an observational surveillance of antibiotic prescribing practices when PCT testing was made available in one US hospital, 10 Swiss centers and 3 French centers \[[@JIV252C22], [@JIV252C23]\]. For the 295 patients evaluated in the United States, adherence to the algorithm was 35%, which was significantly lower than the percentage among algorithm-experienced European centers, suggesting that experience increases confidence and compliance with this approach.

In contrast, studies examining the benefits of viral testing to reduce unnecessary antibiotic use have largely been observational \[[@JIV252C27]--[@JIV252C32]\]. The only randomized clinical trial to date was performed in children and demonstrated significantly less antibiotic use and diagnostic testing for children whose rapid influenza test results were made available to providers, compared with those whose information was withheld \[[@JIV252C33]\]. Although limited by the small sample size, our study suggests that testing for viral pathogens in addition to influenza virus may reduce antibiotic use.

Because confidence in PCT-guided algorithms among US physicians will likely be an iterative process, we focused on patients with nonpneumonic LRTI who were at low risk for bacterial infection, using standard clinical parameters. Adherence to the PCT algorithm was 64%, which was encouraging, given the low US compliance rate in the study by Albrich et al \[[@JIV252C22], [@JIV252C23]\]. However, despite relatively good compliance and a population enriched for subjects with a low risk for bacterial complications, we did not see significant differences in antibiotic use between the intervention and nonintervention arms. We suspect that this result was in part due to a significant study effect resulting in decreased antibiotic exposure in nonintervention patients. Supporting this conclusion was the overall decrease in the duration of antibiotic therapy for nonintervention subjects, compared with the duration for similar historical controls. The study effects were likely multifactorial, including the prestudy educational sessions, spillover care resulting from providers caring for patients in both arms, and increased awareness of viral activity in the community. Last, providers were also aware that their behavior was being observed, which may have resulted in a Hawthorne effect \[[@JIV252C34]\].

Our study had a number of limitations. Because the trial was designed as a feasibility pilot with a small sample size, definitive conclusions cannot be drawn from subgroup analyses, particularly the additive value of viral testing to PCT-guided therapy. Moreover, the study was not powered to determine noninferiority of PCT-guided care, compared with standard treatment algorithms. However, like the European trials, we did not detect any major safety signals prohibitive to proceeding with larger clinical trials. Second, repeat PCT measurements over several days during hospitalization were not performed and may be of added value to decrease antibiotic use. Additionally, routinely available hospital PCR may have diluted the effects of multiplex viral testing. Last, the use of historical controls to evaluate a study effect cannot address other changes in practice that may have occurred unrelated to the study.

Nevertheless, the lessons learned from this study should facilitate the design of larger, definitive US trials. Although our study clearly demonstrates the feasibility of performing PCT trials in the United States, a number of factors need consideration. First, hospital stays for nonpneumonic LRTI tend to be brief, and thus the opportunity to intervene is limited. To maximize impact on antibiotic exposure, the intervention should begin early, ideally in the emergency department. Second, algorithm adherence needs to improve, although clinical judgment remains the cornerstone of good medical care, and 100% compliance should not be the goal. Future trials should therefore incorporate strategies to influence physician behavior, such as the use of antibiotic stewardship teams to reinforce PCT algorithm recommendations. Because a study effect appeared to be an important impediment to demonstrating a significant difference in antibiotic exposure or the independent effect of viral testing, future trials may need to use separate but comparable study sites for the intervention and nonintervention groups. Finally, once the safety of PCT-guided care in patients with LRTI at lower risk for bacterial infections has been established, its use should also be explored for subjects with pneumonic disease.

In conclusion, despite the modest changes in antibiotic exposure observed in the primary analysis, the results of the subgroup analyses and comparison with historical controls are encouraging because they suggest that US physicians will respond to viral and biomarker data. Ultimately, further studies are needed to assess the value of viral testing and to determine the role of PCT-guided care as a practical and effective treatment protocol for patients admitted with nonpneumonic respiratory illnesses.
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